Rab Prinjha
Directeur/Membre du Conseil chez Padlock Therapeutics, Inc.
Postes actifs de Rab Prinjha
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Rab Prinjha
Anciens postes connus de Rab Prinjha
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GSK PLC | Corporate Officer/Principal | - | - |
Formation de Rab Prinjha
| University College London | Doctorate Degree |
Statistiques
Internationale
| Royaume-Uni | 3 |
| Etats-Unis | 2 |
Opérationnelle
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GSK PLC | Health Technology |
| Entreprise privées | 1 |
|---|---|
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Rab Prinjha
- Expérience